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We identified two mutations in a heterozygous state: PAX4 gene, exon 1, PAX4,c.109C>T,p.(Arg37Trp) and BLK gene exon 5, BLK, c.335T>C, p.(Phe112Ser) . Both mutations have been already described in the literature. Mutation PAX4,p.(Arg37Trp) has been found in a heterozygous state in one african patient from Cameroon with KPD. The authors could show that Arg37Trp affects the DNA-binding domain of the molecule and in vitro shows a 50% reduction of PAX4-binding activity to target gene promoters resulting in a similar decrease of normal PAX4 transcriptional repression activity (1). Here we describe this mutation for the second time in an african patient from Nigeria with KPD. The second mutation BLK,p.(Phe112Ser) has been associated with hypertriglyceridaemia (2) but triglycerides in our patient were normal at admission. Amino acid position 112 in the BLK gene is located in the functional SH3-domain of the BLK protein. "in-silico Analysis" of the mutation BLK,c.335T>C, p.(Phe112Ser) using the mutation analysis software ALAMUT (version 2.7.2) shows a high probability for a clinical relevance.
Co-inheritance of both mutations was never published before. Both mutations are located in evolutionarily highly conserved sequence motifs across many species boundaries indicating that they are highly likely pathogenic mutations. Further functional protein studies are needed to confirm PAX4 and BLK mutational analysis as a useful tool in clinical practice of KPD. Identification of the underlying genetic causes of KPD will give a better view of the mechanisms that contribute to the pathophysiology of the disease. Furthermore, proper identification may improve options to prevent KPD. 
